Indian J Pharm Sci. 2015 Jan-Feb;77(1):96-102. doi: 10.4103/0250-474x.151604.

Protective effect of sitagliptin and rosuvastatin combination on vascular endothelial dysfunction in type-2 diabetes.

Indian journal of pharmaceutical sciences

Vandana S Nade, L A Kawale, K M Patel

PMID: 25767324 PMCID: PMC4355889 DOI: 10.4103/0250-474x.151604

Abstract

The present investigation aimed to evaluate the protective effects of sitagliptin, glimepiride, rosuvastatin and their combinations on oxidative stress and endothelial dysfunction in the aortic tissues in fructose-fed type-2 diabetic rats. Sitagliptin (20 mg/kg, p.o.), glimepiride (2 mg/kg, p.o.), rosuvastatin (5 mg/kg, p.o.) and their combinations were administered for 6 w after induction of diabetes by fructose (66%, w/v solution, p.o. for 8 w) in wistar rats. The effects were examined on body weight, serum glucose, triglyceride, cholesterol, blood pressure, heart rate, nitric oxide and antioxidant defensive enzymes. After completion of treatment schedule, the blood pressure was determined by invasive method and vascular reactivity was tested with adrenaline, noradrenaline and phenylephrine. Endothelial dysfunction was determined by acetylcholine and sodium nitroprusside-induced vasorelaxation studies on isolated rat aortas. Long term treatments significantly decreased body weight gain, serum glucose, triglyceride and cholesterol levels; normalize the heart rate, and blood pressure in fructose fed rats. The treatments significantly improved vascular reactivity to catecholamines with reduction in elevated blood pressure in type-2 diabetic rats. The significant improvement in the relaxant response to acetylcholine and sodium nitroprusside was obtained on isolated aortas. All the treatments were effective in restoring defensive antioxidant enzymes. Sitagliptin and rosuvastatin were able to reverse endothelial dysfunction in type-2 diabetes, but better ameliorating potential was found when used in combination.

Keywords: Endothelial dysfunction; blood pressure; catecholamines; vascular reactivity

References

1. Cardiovasc Toxicol. 2011 Jun;11(2):134-47 - PubMed
2. Circulation. 2005 May 17;111(19):2518-24 - PubMed
3. Hypertension. 1987 Nov;10(5):512-6 - PubMed
4. Ann Pharmacother. 2006 Jul-Aug;40(7-8):1336-43 - PubMed
5. Coron Artery Dis. 1999;10(1):23-30 - PubMed
6. Clin Biochem. 2004 Jan;37(1):1-9 - PubMed
7. Biochem Pharmacol. 2007 May 1;73(9):1367-75 - PubMed
8. Br J Pharmacol. 2000 Jul;130(5):963-74 - PubMed
9. Diabetes. 2003 Sep;52(9):2396-402 - PubMed
10. Curr Opin Rheumatol. 2005 May;17(3):286-92 - PubMed
11. J Cardiovasc Pharmacol. 1998;32 Suppl 3:S54-61 - PubMed
12. Circ Res. 2000 Nov 10;87(10):840-4 - PubMed
13. Anal Biochem. 1982 Oct;126(1):131-8 - PubMed
14. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10045-8 - PubMed
15. Arch Biochem Biophys. 1978 Feb;186(1):189-95 - PubMed
16. Circ Res. 1994 Jun;74(6):1141-8 - PubMed
17. Braz J Med Biol Res. 1997 Sep;30(9):1081-6 - PubMed
18. J Appl Physiol. 1973 Feb;34(2):279-82 - PubMed
19. Int J Obes Relat Metab Disord. 2002 Nov;26(11):1407-33 - PubMed
20. Diabetes Metab. 2001 Sep;27(4 Pt 1):436-47 - PubMed
21. Diabetes. 2006 Jun;55(6):1695-704 - PubMed
22. Endocrinology. 2007 May;148(5):2181-8 - PubMed
23. Biochem J. 1966 Jun;99(3):667-76 - PubMed
24. Am J Med. 2003 Dec 8;115 Suppl 8A:99S-106S - PubMed

Publication Types

• Journal Article